In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Bluebird bio Inc (NASDAQ: BLUE) was $8.46 for the day, down -6.21% from the previous closing price of $9.02. In other words, the price has decreased by -$6.21 from its previous closing price. On the day, 0.18 million shares were traded. BLUE stock price reached its highest trading level at $9.1682 during the session, while it also had its lowest trading level at $8.45.
Ratios:
Our analysis of BLUE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.33 and its Current Ratio is at 0.51.
On November 15, 2024, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $3 to $0.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’25 when Colvin Richard A sold 19 shares for $9.24 per share. The transaction valued at 176 led to the insider holds 8,257 shares of the business.
Obenshain Andrew sold 140 shares of BLUE for $1,294 on Jan 06 ’25. The President and CEO now owns 18,571 shares after completing the transaction at $9.24 per share. On Jan 06 ’25, another insider, Colvin Richard A, who serves as the Officer of the company, bought 19 shares for $8.74 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLUE now has a Market Capitalization of 82249984 and an Enterprise Value of 321886080. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.55. Its current Enterprise Value per Revenue stands at 5.863 whereas that against EBITDA is -1.065.
Stock Price History:
The Beta on a monthly basis for BLUE is 0.69, which has changed by -0.6934782 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, BLUE has reached a high of $38.40, while it has fallen to a 52-week low of $5.80. The 50-Day Moving Average of the stock is 1.96%, while the 200-Day Moving Average is calculated to be -44.25%.
Shares Statistics:
BLUE traded an average of 412.51K shares per day over the past three months and 301350 shares per day over the past ten days. A total of 9.70M shares are outstanding, with a floating share count of 9.64M. Insiders hold about 0.88% of the company’s shares, while institutions hold 34.14% stake in the company. Shares short for BLUE as of 1730332800 were 47705814 with a Short Ratio of 6.01, compared to 1727654400 on 48991273. Therefore, it implies a Short% of Shares Outstanding of 47705814 and a Short% of Float of 26.66.
Earnings Estimates
The current rating of Bluebird bio Inc (BLUE) is the result of assessments by 4.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$4.05, with high estimates of -$2.42 and low estimates of -$5.67.
Analysts are recommending an EPS of between -$24.55 and -$34.6 for the fiscal current year, implying an average EPS of -$29.22. EPS for the following year is -$10.28, with 4.0 analysts recommending between $0.3 and -$23.6.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $30.4M to a low estimate of $18M. As of the current estimate, Bluebird bio Inc’s year-ago sales were $7.83MFor the next quarter, 8 analysts are estimating revenue of $37.91M. There is a high estimate of $53.3M for the next quarter, whereas the lowest estimate is $20M.
A total of 9 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $78.38M, while the lowest revenue estimate was $63.3M, resulting in an average revenue estimate of $72.08M. In the same quarter a year ago, actual revenue was $29.5MBased on 9 analysts’ estimates, the company’s revenue will be $244.91M in the next fiscal year. The high estimate is $383.8M and the low estimate is $145.9M.
